Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.

King GT, Sharma P, Davis SL, Jimeno A.

Drugs Today (Barc). 2018 Feb;54(2):103-122. doi: 10.1358/dot.2018.54.2.2776626.

PMID:
29637937
2.

Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression.

Keysar S, Eagles J, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset H, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, Jimeno A.

Clin Cancer Res. 2018 Mar 19. pii: clincanres.3871.2018. doi: 10.1158/1078-0432.CCR-17-3871. [Epub ahead of print]

PMID:
29555661
3.

Bispecific antibodies for cancer therapy: A review.

Krishnamurthy A, Jimeno A.

Pharmacol Ther. 2018 May;185:122-134. doi: 10.1016/j.pharmthera.2017.12.002. Epub 2017 Dec 18. Review.

PMID:
29269044
4.

FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation.

Dionne LK, Peterman E, Schiel J, Gibieža P, Skeberdis VA, Jimeno A, Wang XJ, Prekeris R.

J Cell Sci. 2017 Dec 1;130(23):4051-4062. doi: 10.1242/jcs.208983.

PMID:
29196475
5.

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.

PMID:
29054986
6.

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.

Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC.

Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27.

PMID:
28954784
7.

Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.

Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W.

Ann Surg Oncol. 2018 Mar;25(3):768-775. doi: 10.1245/s10434-017-6082-1. Epub 2017 Sep 8.

PMID:
28887726
8.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
9.

Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.

Krishnamurthy A, Jimeno A.

Drugs Today (Barc). 2017 Apr;53(4):217-237. doi: 10.1358/dot.2017.53.4.2589163. Review.

PMID:
28492290
10.

Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.

Rusthoven CG, Lanning RM, Jones BL, Amini A, Koshy M, Sher DJ, Bowles DW, McDermott JD, Jimeno A, Karam SD.

Radiother Oncol. 2017 Jul;124(1):139-146. doi: 10.1016/j.radonc.2017.03.019. Epub 2017 Apr 19.

PMID:
28433411
11.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

12.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

13.

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.

Eagles JR, Jimeno A.

Drugs Today (Barc). 2016 Nov;52(11):593-605. doi: 10.1358/dot.2016.52.11.2542234. Review.

PMID:
28112278
14.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
15.

Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.

Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD.

Sci Rep. 2016 Dec 12;6:38792. doi: 10.1038/srep38792.

16.
17.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

18.

Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.

Morton JJ, Bird G, Refaeli Y, Jimeno A.

Cancer Res. 2016 Nov 1;76(21):6153-6158. Epub 2016 Sep 1. Review.

19.

Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.

Oweida A, Bhatia S, Hirsch K, Calame D, Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, Wang XJ, Parkash G, Califano J, Karam SD.

Mol Carcinog. 2017 Mar;56(3):1189-1196. doi: 10.1002/mc.22574. Epub 2016 Nov 1.

PMID:
27649287
20.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

21.

Cancer Stem Cells in Squamous Cell Carcinoma.

Jian Z, Strait A, Jimeno A, Wang XJ.

J Invest Dermatol. 2017 Jan;137(1):31-37. doi: 10.1016/j.jid.2016.07.033. Epub 2016 Nov 24. Review.

22.

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A.

J Natl Cancer Inst. 2016 Sep 15;109(1). pii: djw189. doi: 10.1093/jnci/djw189. Print 2017 Jan.

23.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

24.

Emerging from their burrow: Hedgehog pathway inhibitors for cancer.

Gan GN, Jimeno A.

Expert Opin Investig Drugs. 2016 Oct;25(10):1153-66. doi: 10.1080/13543784.2016.1216973. Epub 2016 Aug 5. Review.

PMID:
27459882
25.

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.

Bowles DW, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A.

Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2. doi: 10.1016/j.clcc.2016.03.004. Epub 2016 Mar 31.

PMID:
27118441
26.

Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.

Owsley J, Jimeno A, Diamond JR.

Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528. Review.

PMID:
27092341
27.

Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.

Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD.

Oral Oncol. 2016 May;56:1-7. doi: 10.1016/j.oraloncology.2016.02.011. Epub 2016 Mar 12.

PMID:
27086480
28.

Outbreak of urinary tract infections by Salmonella spp. after cystoscopic manipulation.

Jimeno A, Alcalde MM, Ortiz M, Rodríguez A, Alcaraz B, Vera F.

Actas Urol Esp. 2016 Dec;40(10):646-649. doi: 10.1016/j.acuro.2016.02.005. Epub 2016 Apr 6. English, Spanish.

PMID:
27061662
29.

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A.

Target Oncol. 2016 Jun;11(3):429. No abstract available.

PMID:
27056749
30.

Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.

Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD.

Cancer. 2016 May 15;122(10):1533-43. doi: 10.1002/cncr.29956. Epub 2016 Mar 11.

31.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2016 Jun;27(6):1180. doi: 10.1093/annonc/mdw095. Epub 2016 Mar 3. No abstract available.

PMID:
26945010
32.

Olaparib for the treatment of ovarian cancer.

Bornstein E, Jimeno A.

Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714. Review.

PMID:
26937492
33.

A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.

Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A.

Oral Oncol. 2016 Feb;53:74-9. doi: 10.1016/j.oraloncology.2015.11.014. Epub 2015 Dec 15.

34.

DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation.

Allen CP, Tinganelli W, Sharma N, Nie J, Sicard C, Natale F, King M 3rd, Keysar SB, Jimeno A, Furusawa Y, Okayasu R, Fujimori A, Durante M, Nickoloff JA.

Front Oncol. 2015 Dec 7;5:260. doi: 10.3389/fonc.2015.00260. eCollection 2015.

35.

Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model.

Gan GN, Altunbas C, Morton JJ, Eagles J, Backus J, Dzingle W, Raben D, Jimeno A.

Int J Radiat Biol. 2016;92(1):50-6. doi: 10.3109/09553002.2016.1114189. Epub 2015 Dec 21.

36.

Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.

Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT.

J Clin Pharmacol. 2016 Aug;56(8):966-73. doi: 10.1002/jcph.681. Epub 2016 Feb 2.

37.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Dec;26(12):2505. doi: 10.1093/annonc/mdv477. Epub 2015 Oct 21. No abstract available.

38.

CRB2 completes a fully expressed Crumbs complex in the Retinal Pigment Epithelium.

Paniagua AE, Herranz-Martín S, Jimeno D, Jimeno ÁM, López-Benito S, Arévalo JC, Velasco A, Aijón J, Lillo C.

Sci Rep. 2015 Sep 25;5:14504. doi: 10.1038/srep14504.

39.

Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.

Noonan S, Man Wong K, Jimeno A.

Drugs Today (Barc). 2015 Jun;51(6):357-66. doi: 10.1358/dot.2015.51.6.2319324. Review.

PMID:
26261849
40.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA.

Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.

41.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA.

Int J Cancer. 2016 Jan 1;138(1):195-205. doi: 10.1002/ijc.29676. Epub 2015 Jul 22.

42.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

43.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Sep;26(9):1923-9. doi: 10.1093/annonc/mdv264. Epub 2015 Jun 19. Erratum in: Ann Oncol. 2015 Dec;26(12):2505. Leichman, L [added]. Ann Oncol. 2016 Jun;27(6):1180.

44.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

45.

Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.

Scott AJ, Messersmith WA, Jimeno A.

Drugs Today (Barc). 2015 Apr;51(4):223-9. doi: 10.1358/dot.2015.51.4.2320599. Review.

PMID:
26020064
46.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S.

Clin Cancer Res. 2015 Oct 1;21(19):4356-64. doi: 10.1158/1078-0432.CCR-14-3357. Epub 2015 May 26.

47.

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO).

Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Erratum in: Target Oncol. 2016 Jun;11(3):429.

48.

ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/β-Catenin, Notch and PI3K/Akt Signaling Pathways.

Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V.

PLoS One. 2015 May 7;10(5):e0121648. doi: 10.1371/journal.pone.0121648. eCollection 2015.

49.

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE.

PLoS One. 2015 May 6;10(5):e0123600. doi: 10.1371/journal.pone.0123600. eCollection 2015.

50.

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer.

Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, Gan G, McGettigan B, Fernandez P, Padilla-Just N, Varella-Garcia M, Song JI, Bowles DW, Schedin P, Tan AC, Roop DR, Wang XJ, Refaeli Y, Jimeno A.

Oncogene. 2016 Jan 21;35(3):290-300. doi: 10.1038/onc.2015.94. Epub 2015 Apr 20.

Supplemental Content

Loading ...
Support Center